The "failure" has, as Dr. Nissen and colleagues, article demonstrates, advanced our understanding. I have been a severe critic of Nissen with respect to his pronouncements on the safety of ADHD drugs, but as this article suggests, his handling of the torcetrapib issue has been thoughtful, responsible and in some respects visionary.
More needs to be written about this unfolding saga -- as well as other struggles to understand the intimate connection between disease, body, molecule, genetics. It might promote the growth of something lack among those eager to issue pronouncements about how companies should run their businesses: humility. As Derek Lowe of www.corante.com has noted, on a good day scientists walk into a lab not knowing what to expect, The NEJM shows that real money is invested on this proposition every.